Organization
Respiratory Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
4 abstracts
Abstract
Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results.Org: Zhejiang Cancer Hospital, Hangzhou, China, Clinical Trial Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, China, The First Hospital of China Medical University, Shenyang, China, The Affiliated Cancer Hospital of Xinjiang Medical University, Wulumuqi, China, Second Affiliated Hospital of Nanchang University, Nanchang, China,
Abstract
Phase II study of anlotinib plus durvalumab and chemotherapy as first-line treatment in extensive-stage small cell lung cancer (ES-SCLC): Efficacy and safety analysis.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Respiratory Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China,
Abstract
FAK inhibition with novel FAK/ALK inhibitor APG-2449 could overcome resistance in NSCLC patients who are resistant to second-generation ALK inhibitors.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Hunan Provincial Oncology Hospital, Zhejiang Cancer Hospital, Chinese Academy of Sciences, Respiratory Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,
Abstract
Phase II results of ivonescimab (AK112/ SMT112), a novel PD-1/VEGF bispecific, in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK.Org: Sun Yat-sen University Cancer Center, Guangzhou, China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Hunan Cancer Hospital, Changsha, China, Yunnan Cancer Hospital, Kunming, China, The First Affiliated Hospital of Anhui Medical University, Hefei, China,